About Professor Richard Hindley

Consultant Urologist

Men's Health

Sub-specialties: Men's Health, Urology, Prostate, Urological Cancer, Prostate Cancer Diagnostics, Focal Therapy for Prostate Cancer, Minimally Invasive Treatments for Men with Symptomatic BPH, Urinary Tract Infections (UTI).

Professor Richard Hindley is a Consultant Urologist at OneWelbeck Men's Health

Overview

Bookings: bookings.menshealth@onewelbeck.com

Tel: 020 3653 2042

Professor Richard Hindley is a Consultant Urologist at OneWelbeck Men's Health

Areas of Expertise

Professor Richard Hindley performs a range of treatments including:

  • Greenlight laser
  • Rezum
  • Focal therapy for prostate cancer
  • Minimally invasive treatments for men with symptomatic BPH
  • Aquablation
  • Transperineal fusion guided prostate biopsies.

He commonly treats: 

  • Prostate cancer
  • Symptoms due to benign prostate enlargement (BPH), and also prostatitis

About Professor Richard Hindley

Appointed as a Consultant Urologist in 2004 following a fellowship in Brisbane in 2003. Initially appointed as a laparoscopic surgeon for upper urinary tract malignancy and prostate cancer diagnostics and BPH. Within 2 years of his appointment, he had introduced the Greenlight laser procedure for men with benign prostate problems as well as HIFU treatment for prostate cancer. Always interested in research and innovation Richard has collaborated closely with UCLH, Imperial and Oxford Universities. He was a key member of the team working with the MRC to set up and recruit to the groundbreaking PROMIS trial which has forever changed the diagnostic pathway for men with suspected prostate cancer with the incorporation of multiparametric MRI as the triage tool prior to biopsy. Increasingly the majority of his work both clinical and academic is focussed on the prostate. He has now published over 100 predominantly prostate related publications in the urological literature. In 2017 he was awarded a visiting professor position at the University of Winchester in recognition of this. He is currently working on a project to improve decision-making for men facing a multitude of treatment options for benign prostate problems.
In early 2017 he performed the first UK cases of Rezum water vapour therapy for men with symptoms due to benign prostate enlargement, and is now a recognised key opinion leader in the field of minimally invasive prostate treatments with experience of the majority of treatment options currently available. He is also one of very few urologists in Europe to have approaching 15 years of experience of focal therapy for prostate cancer. He is currently working on projects to try and reduce the National waiting list for men waiting for BPH treatments, and he has just recently received a research grant of £1M to investigate further the use of prostate AI in collaboration with Lucida Medical.

Reviews

Additional Information

Memberships

  • British Association of Urological Surgeons (BAUS)
  • European Association of Urology (EAU)
  • British Medical Association (BMA)

Research Highlights

Evaluation of Outcomes Following Focal Ablative Therapy for Treatment of Localized Clinically Significant Prostate Cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-Year Experience.

Habashy D, Reddy D, Peters M, Shah TT, van Son M, van Rossum PSN, Tanaka MB, Cullen E, Engle R, McCracken S, Greene D, Hindley RG, Emara A, Nigam R, Orczyk C, Shergill I, Persad R, Virdi J, Moore CM, Arya M, Winkler M, Emberton M, Ahmed HU, Dudderidge T.

J Urol. 2023 Jul;210(1):108-116. doi: 10.1097/JU.0000000000003443. Epub 2023 Apr 4. PMID: 37014172

Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.

Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham AP, Oldroyd R, Parker C, Emberton M; PROMIS study group.

Lancet. 2017 Feb 25;389(10071):815-822. doi: 10.1016/S0140-6736(16)32401-1. Epub 2017 Jan 20.

PMID: 28110982 Free article.

Minimally invasive surgery for benign prostatic obstruction: new insights and future technical standards.

Rijo E, Hindley R, Tabatabaei S, Bach T.

Curr Opin Urol. 2021 Sep 1;31(5):461-467. doi: 10.1097/MOU.0000000000000918.

PMID: 34231545 Review.

Real-world Early Outcomes and Retreatment Rates Following Water Vapour Ablative Therapy for Symptomatic Benign Prostatic Hyperplasia.

Whiting D, Noureldin M, Abdelmotagly Y, Johnston MJ, Brittain J, Rajkumar G, Emara A, Hindley R.

Eur Urol Open Sci. 2022 Apr 7;39:72-78. doi: 10.1016/j.euros.2022.03.006. eCollection 2022 May.

PMID: 35528787 Free PMC article.

Reaching a Tipping Point: A Qualitative Exploration of Quality of Life and Treatment Decision-Making in People Living With Benign Prostatic Hyperplasia.

Husted M, Gray D, Golding SE, Hindley R.

Qual Health Res. 2022 Nov;32(13):1979-1992. doi: 10.1177/10497323221129262. Epub 2022 Sep 26.

PMID: 36154347 Free PMC article.